Researchers Created Mouse Model for AMD Risk Variant
Scientists used CRISPR-Cas9 to develop a new animal model that mimics human macular degeneration characteristics.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you believe animal research is essential for developing new medical treatments?
Researchers have successfully generated a mouse model for the human ARMS2 A69S AMD risk variant, a key genetic factor linked to age-related macular degeneration. The new model provides a vital tool for studying disease mechanisms that were previously difficult to investigate due to the absence of the ARMS2 gene in rodents.
Why it matters
The model was created to help researchers better understand the underlying causes of AMD and evaluate potential therapeutic interventions. Given the lack of existing animal models, this development offers a significant step forward in translating genetic risk into effective medical treatments.
Researchers utilized CRISPR-Cas9 to insert the human ARMS2 A69S gene into the mouse Chromosome 7, placing it 3.5 kb upstream of Htra1. The model exhibits reduced mitochondrial respiration and scotopic ERG amplitudes, with notable thinning of the outer nuclear layer appearing by 12 months.
The players
CRISPR-Cas9
This is a specialized genome-editing technology that allows researchers to precisely alter DNA sequences within living organisms.
The details
By inserting the human ARMS2 gene into the mouse genome, researchers were able to express the variant in retinal horizontal cells and the retinal pigment epithelium. This modification resulted in reduced retinal mtDNA copy numbers and specific structural retinal phenotypes that mirror aspects of human macular degeneration.
Timeline
Retinal and RPE transcriptomic profiling was conducted at postnatal day 14.
Mice develop AMD-relevant retinal phenotypes by age 12 months.
The Big Picture
This development marks a significant shift in retinal research by addressing the genetic gap that has long hindered the study of the Chromosome 10q26 AMD risk locus. By providing a functional in vivo system, this work allows scientists to move beyond association studies to directly testing the mechanisms that lead to cellular degeneration.
This research serves as a foundational step toward identifying new therapeutic targets for age-related macular degeneration. While currently in the laboratory stage, the model provides a necessary platform for testing drugs that could eventually slow or prevent vision loss in patients.
The takeaway
The creation of this mouse model addresses a critical limitation in macular degeneration research by allowing for direct observation of the ARMS2 gene variant. Researchers now possess an actionable tool to study mitochondrial health and retinal integrity in a controlled environment.
Further reading
For more on the current landscape of genetic research, explore our Biotech section.
More information
Read the complete biorxiv research study publication.
Source note: This article includes information reported by Biorxiv.
Live Poll
Do you believe animal research is essential for developing new medical treatments?
